X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Enhancing Gene Therapy Manufacturing, The PAT Project Vision

Content Team by Content Team
14th September 2023
in News

The Cell and Gene Therapy Catapult is embarking on a two-year project in collaboration with two other organizations, namely contract development and manufacturing organization (CDMO) Rentschler Biopharma and Refeyn Ltd. Their objective is to enhance the manufacturing process of adeno-associated viruses (AAV) used in gene therapies by incorporating automated and digital process analytical technologies (PAT).

More than 65 percent of gene therapies in development currently rely on AAV. Still, their production is intricate and time-consuming, primarily due to the conventional manual sampling methods employed for analytical purposes.

What does the PAT project entail?

The new PAT project aims to create an automated platform for gene therapy manufacturing. This system will be integrated into Rentschler Biopharma’s existing AAV manufacturing process.

It involves the automation of high-throughput sampling and analysis of AAV materials. The data generated will be utilized to construct digital replicas, allowing initial testing of process modifications in a virtual environment. A significant advantage of this approach is the potential reduction in physical laboratory tests required.

The collaborators will evaluate any enhancements in productivity and AAV yield resulting from adopting automated analytical technologies.

The Chief Executive of the Cell and Gene Therapy Catapult Matthew Durdy expressed, “We anticipate that this collaboration will substantially contribute to advancing the industry’s manufacturing capabilities.”

Potential outcomes for gene therapy manufacturing

The potential for expedited development of viral vectors, driven by multi-parameter optimization, promises increased output, enhanced robustness, and improved process control. Ultimately, this could mitigate the risks associated with transitioning from early-stage to late-stage manufacturing, as highlighted by Dr. Christian Schetter, Chief Scientific Officer of Rentschler Biopharma.

The PAT project is financially supported through a grant from Innovate UK, specifically designated for digitalizing and automating medicines research and manufacturing.

Previous Post

Drug Portfolio Restrictions Imposed By The FTC On Amgen

Next Post

Over 50% Of FDA-Approved Drugs To Incorporate AI By 2030

Related Posts

DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Drug Development

Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

21st March 2025
Clinical Trials

Oracle Wins the Asia Pacific Biopharma Excellence Awards

21st March 2025
Clinical Trials

Bio-Rad to Acquire Stilla Technologies by Q3 2025

28th February 2025
Next Post

Over 50% Of FDA-Approved Drugs To Incorporate AI By 2030

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In